


2019

medicina

BUENOS AIRES VOL. 79 Supl. IV - 2019

80° Aniversario



MEDICINA

Volumen 79, Supl. IV, págs. 1-338

medicina

BUENOS AIRES, VOL. 79 Supl. IV - 2019

COMITÉ DE REDACCIÓN

Pablo J. Azurmendi
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Damasia Becú Villalobos
Instituto de Biología y Medicina Experimental-CONICET, Buenos Aires, Argentina

José H. Casabé
Instituto de Cardiología y Cirugía Cardiovascular, Hospital Universitario Fundación Favaloro, Buenos Aires, Argentina

Eduardo L. De Vito
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Isabel Narvaiz Kantor
Organización Panamericana de la Salud (OPS/OMS) (ret.) Argentina

Basilio A. Kotsias
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Gustavo Kusminsky
Hospital Universitario Austral, Buenos Aires, Argentina

Isabel A. Lüthy
Instituto de Biología y Medicina Experimental (IBYME), Buenos

Aires, Argentina

Daniel A. Manigot
Hospital San Juan de Dios, Buenos Aires, Argentina

Jorge A. Manni
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Rodolfo S. Martin
Facultad de Ciencias Biomédicas y Hospital Universitario Austral, Buenos Aires, Argentina

Guillermo D. Mazzolini
Instituto de Investigaciones en Medicina Traslacional-CONICET, Hospital Universitario Austral, Buenos Aires, Argentina

Rodolfo C. Puche
Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Santa Fe, Argentina

Viviana Ritacco
Instituto Nacional de Enfermedades Infecciosas ANLIS-CONICET, Buenos Aires, Argentina

Guillermo B. Semeniuk
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

MIEMBROS EMÉRITOS

Héctor O. Alonso
Instituto Cardiovascular Rosario, Santa Fe, Argentina

Guillermo Jaim Etcheverry
Facultad de Medicina, UBA, Argentina

María Marta de Elizalde de Bracco
IMEX-CONICET-Academia Nacional de Medicina, Buenos Aires,

Argentina

Christiane Dosne Pasqualini
Academia Nacional de Medicina, Buenos Aires, Argentina

La Tapa (Ver pág. 4)
Atardecer en la tarde
Antonella Ricagni

MEDICINA (Buenos Aires) – Revista bimestral – ISSN 0025-7680 (Impresa) – ISSN 1669-9106 (En línea)

REVISTA BIMESTRAL

Registro de la Propiedad Intelectual N° 02683675

Personería Jurídica N° C-7497

Publicación de la Fundación Revista Medicina (Buenos Aires)

Propietario de la publicación: **Fundación Revista Medicina**

Queda hecho el depósito que establece la Ley 11723

Publicada con el apoyo del Ministerio de Ciencia, Tecnología e Innovación Productiva.

MEDICINA no tiene propósitos comerciales. El objeto de su creación ha sido propender al adelanto de la medicina argentina.

Los beneficios que pudieran obtenerse serán aplicados exclusivamente a este fin.

Aparece en MEDLINE (PubMed), ISI-THOMSON REUTERS (Journal Citation Report, Current Contents, Biological Abstracts, Biosis, Life Sciences), CABI (Global Health), ELSEVIER (Scopus, Embase, Excerpta Medica), SciELO, LATINDEX, BVS (Biblioteca Virtual en Salud), DOAJ, Google Scholar y Google Books.

Incluida en el Núcleo Básico de Revistas Científicas Argentinas del CONICET.

Directores Responsables:

Basilio A. Kotsias, Eduardo L. De Vito, Isabel Narvaiz Kantor, Guillermo B. Semeniuk

Secretaría de Redacción: Ethel Di Vita, Instituto de Investigaciones Médicas Alfredo Lanari, Combatientes de Malvinas 3150,

1427 Buenos Aires, Argentina

Tel. 5287-3827 Int. 73919 y 4523-6619

e-mail: revmedbuenosaires@gmail.com – http://www.medicinabuenosaires.com

Vol. 79, Supl. IV, Noviembre 2019

REUNIÓN ANUAL DE SOCIEDADES DE BIOCIENCIA 2019

**LXIV Reunión Anual de la
Sociedad Argentina de Investigación Clínica (SAIC)**

**LI Reunión Anual de la
Asociación Argentina de Farmacología Experimental (SAFE)**

**XXI Reunión Anual de la
Sociedad Argentina de Biología (SAB)**

**XXXI Reunión Anual de la
Sociedad Argentina de Protozoología (SAP)**

**IX Reunión Anual de la
Asociación Argentina de Nanomedicinas
(NANOMED-ar)**

**VI Reunión Científica Regional de la Asociación Argentina de Ciencia y
Tecnología de Animales de Laboratorio (AACyTAL)**

**con la participación de
The Histochemical Society**

13 - 16 de noviembre de 2019
Hotel 13 de Julio - Mar del Plata

EDITORES RESPONSABLES

**Dra. Mónica Costas
Dra. Gabriela Marino
Dr. Pablo Azurmendi**

Yanina Alejandra SANTANDER PLANTAMURA (1) | Camila BOQUETE(2) | Miguel ALLO(2) | Luciano PAROLA(2) | Ariel POLIZIO(2) | Christian HOCHT(2) | Susana GORZALCZANY(2)

CÁTEDRA DE FARMACOLOGÍA. FACULTAD DE CIENCIAS EXACTAS. UNLP./ CONICET (1); CÁTEDRA DE FARMACOLOGÍA, FACULTAD DE FARMACIA Y BIOQUÍMICA, UBA (2)

Abstract/Resumen: Introduction The imbalance between reactive oxygen species and nitric oxide is implicated in the pathogenesis of hypertension. Several studies have provided evidence of the role of an impaired glutation (GSH) system in the development of hypertension. Furthermore, N-acetylcysteine (NAC) improves NO bioavailability reducing blood pressure in adult spontaneously hypertensive rats (SHR). Nebivolol is a third-generation beta-blocker that combines beta-adrenergic blocking activity with a vasodilating effect mediated by the endothelial nitric oxide (eNOS) pathway. In the current study, we aimed to examine the effect of chronic oral treatment with the combination of nebivolol and NAC on hemodynamic and histological parameters in normotensive and SHR rats. Four weeks-old female SHR, and control normotensive male Wistar Kyoto rats (WKY) were randomly assigned into 3 groups (n=10/group): Group 1, WKY without treatment; Group 2, SHR without treatment; and Group 3 (SHR + NAC), which received 0.6 % NAC in drinking water. Two months later rats were randomly assigned into 5 groups: Group 1, WKY without treatment; Group 2, SHR without treatment; Group 3, SHR with nebivolol (15 mg/kg/day); Group 4, (SHR+NAC) which received 0.6 % NAC in drinking water, and Group 5, (SHR+NAC+NEBI), which received NAC plus NEBI. Systolic blood pressure (SBP) was measured in conscious rats by indirect tail-cuff. Furthermore, we measured the mean arterial pressure (MAP) in freely moving rats after carotid cannulation. All rats were sacrificed at the age of 16 weeks. Target organ damage at the left ventricle was evaluated by histological analysis after Sirius red staining. The SBP measured by tail-cuff was significantly reduced in group 5 (SHR+NAC+NEBI) (mmHg; SHR: 181 ± 15 vs. SHR+NAC+NEBI: 155 ± 6, p<0.05), although the MAP was significantly reduced by NEBI alone or in combination with NAC (mmHg; SHR+NEBI: 166 ± 7, SHR+NAC+NEBI: 175 ± 14 vs. SHR: 201 ± 10, p<0.05). On the other hand, the histological analysis of left ventricle shows a significant reduction on fibrosis interstitial with all the treatments (FCI%, SHR+ NEBI: 0.54 ± 0.21, SHR+NEBI+NAC: 0.84 ± 0.13, NAC: 0.49 ± 0.16 vs. SHR: 1.65 ± 0.40, p<0.05). The increased of the size of cardiomyocytes (μm^2 , SHR: 725 ± 96, WKY: 449 ± 93, p<0.05), although the MAP was not prevented by any treatment (μm^2 , SHR+NEBI: 693 ± 154, SHR+NAC: 707 ± 107, SHR+NEBI+NAC: 575 ± 86) The combination of nebivolol plus NAC was able to prevent the hemodynamic alterations in this model, and markers of organ target damage such as left ventricle fibrosis in SHR rats. Despite nebivolol alone does not modify peripheral SBP in SHR rats, it was able to partially prevent the increase of MAP and the fibrosis on the left ventricle.

Biología celular y molecular de procesos fisiológicos y patológicos / Biology IV

Chairs: Graciela Calabrese | Evangelina Capobianco

0411 - ANALYSIS OF MRP4/ABCC4-INDUCED EPIGENETIC SIGNATURE IN PANCREATIC CANCER

Samanta Nerea GANCEDO | Betina GONZÁLEZ | Ana SAHORES | Natalia GÓMEZ | Rodrigo LAGOS | Carolina GHANEM | Carlos DAVIO

ININFA

Abstract/Resumen: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with a dismal prognosis. Histone deacetylases (HDACs) and demethylases (KDMs), as well as DNA

methylases (DNMTs) and demethylases (TETs), are epigenetic modulators whose activity is frequently deregulated in various cancers including PDAC. In particular, HDAC1 and HDAC2 have been shown to play an important role in the control of proliferation, apoptosis, differentiation, migration, and angiogenesis of PDAC cells. The multidrug resistance-associated protein 4 MRP4/ABCC4 is a xenobiotic transporter involved in the regulation of cAMP signaling by extrusion to the extracellular compartment. MRP4 was found highly expressed in PDAC, and its expression correlates with increased proliferation and poor prognosis. MRP4 overexpression in the PDAC cell line BxPC-3 increased proliferation, and cell inoculation in NGS mice produced xenografts with increased weight and poor differentiation compared to mock tumors. Therefore, we aimed to analyze how MRP4 overexpression collaborates in PDAC malignant epigenetic and transcriptional signature that enables tumor progression. We analyzed the expression of several epigenetic modulators in MRP4-overexpressing BxPC-3 tumors (MRP4+), compared to wild type tumors (WT) and tumors transfected with an empty vector (mock). We found increased HDAC1 and HDAC2 mRNA and protein levels, and concomitantly decreased acetylation of H3K9ac, in MRP4+ compared to WT/mock (p<0.05). MRP4+ tumors also showed increased mRNA expression of key enzymes involved in epigenetic control of cancer progression: Sirt1 and Kdm1a (LSD1), involved in histone deacetylation and demethylation, and Dnmt1 and Tet1, linked to aberrant methylation/demethylation patterns in DNA. These findings suggest that, in pancreatic cancer, MRP4 contributes to the establishment of an aberrant epigenetic signature and altered transcriptional program which may drive cells towards a proliferative and undifferentiated phenotype.

0520 - RETINOID X RECEPTOR ´S ACTIVATION MODULATES A CROSSTALK BETWEEN NRF2 AND NFKB PATHWAY IN RETINAL PIGMENT EPITHELIUM CELLS UPON H₂O₂ TREATMENT

Victoria Belen AYALA-PEÑA | Olga Lorena GERMAN

INIBIBB-CONICET, DEPTO. BIOLOGÍA, BIOQUÍMICA Y FARMACIA-UNS

Abstract/Resumen: Age-related macular degeneration (AMD) is the main pathology leading to blindness in adults and has no cure or effective treatment. Retinal pigment epithelial (RPE) cells have immunomodulatory properties and their degeneration contributes in AMD development. Oxidative stress is also involved in the pathogenesis of this disease. We have demonstrated that RXR activation with HX630 protects RPE (D407) cells from H₂O₂-induced apoptosis, and prevents NfκB nuclear translocation. Also, our previous results suggested RXR-PPARγ as the main heterodimer involved. In this work we investigate the RXR-PPARγ involvement in the mentioned protective effect and its mechanism of action. For that, D407 were treated or not with H₂O₂, HX630 and/or a PPARγ specific agonist (Pioglitazone: PG). We analyzed cell viability by MTT assay and DAPI stained; and studied NfκB pathway (which modulates inflammation and apoptosis) and Nrf2 (which activates cytoprotective genes and regulates NfκB pathway) by qRT-PCR, fluorescence microscopy and Western-blot. PG reproduced the inhibition of NfκB translocation and the protective effect of RXR activation against oxidative damage. PG inhibited the IκBα phosphorylation more than HX630, while it promoted IκBα synthesis. When HX630 and PG were together, the inhibition of NfκB translocation was higher than the agonists alone, although, there was no synergism in apoptosis prevention. HX630 increases Nrf2 synthesis, PG does not, and both agonists together decrease Nrf2 levels suggesting proteosomal degradation. As a whole, our results show that RXR and PPARγ agonists together potentiate the anti-inflammatory response but not the antiapoptotic effects of each agonist alone on RPE cells upon oxidative stress, and suggest that both agonists are necessary together to alter the crosstalk between Nrf2 and NfκB pathway.